Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Bausch Health Sues Alvogen to Block Copies of Xifaxan IBS Drug

March 27, 2020, 2:17 PM

Bausch Health said Alvogen’s proposed generic version of a treatment for irritable bowel syndrome with diarrhea infringes 23 patents for Xifaxan 550 milligram tablets.

  • Bausch is seeking a court order blocking copies until the patents have expired, according to complaint filed Thursday in federal court in Wilmington, Delaware
  • Patents expire in June 2024; February and June 2025; February 2026; September 2027; February, July and October 2029; and March 2030, according to supplemental filing
  • Closely held Alfasigma owns 13 of the patents and exclusively licenses them to Bausch, complaint says
  • Xifaxan had sales of $1.45 billion in 2019, 16.9% of ...